Beyond Depigmentation: Understanding the Psychosocial Burden of Vitiligo in a Canadian Context
Résumé
Vitiligo is a common cutaneous autoimmune disorder presenting with depigmented patches of skin. It is often described in textbooks as a cosmetic disease, with disease manifestations confined to the skin. However, for many patients living with vitiligo, this characterization could not be further from the truth.
In recent years, the approval of ruxolitinib cream (Opzelura), a topical Janus kinase (JAK)1/2 inhibitor, has renewed clinical and research interest in vitiligo. Prior to this advancement, treatment options for the disease had remained limited. Coupled with this shift in management, emerging evidence highlights that the impact of vitiligo goes well beyond the skin. As new therapies emerge, a nuanced understanding of the disease’s psychosocial impact is paramount to informing dermatologic care, guiding equitable access to treatment, and shaping dermatologic policy within the Canadian context.
Références
Bibeau K, Pandya AG, Ezzedine K, Jones H, Gao J, Lindley A, et al. Vitiligo prevalence and quality of life among adults in Europe, Japan and the USA. J Eur Acad Dermatol Venereol. 2022;36(10):1831-1844. doi:10.1111/jdv.18257.
Bergqvist C, Ezzedine K. Vitiligo: a review. Dermatology. 2020;236(6):571-592. doi:10.1159/000506103.
Pahwa P, Mehta M, Khaitan BK, Sharma VK, Ramam M. The psychosocial impact of vitiligo in Indian patients. Indian J Dermatol Venereol Leprol. 2013;79(5):679-685. doi:10.4103/0378-6323.116737.
Ezzedine K, Eleftheriadou V, Jones H, Bibeau K, Kuo FI, Sturm D, et al. Psychosocial effects of vitiligo: a systematic literature review. Am J Clin Dermatol. 2021;22(6):757-774. doi:10.1007/s40257-021-00631-6
Bibeau K, Ezzedine K, Harris JE, van Geel N, Grimes P, Parsad D, et al. Mental health and psychosocial quality-of-life burden among patients with vitiligo: findings from the Global VALIANT Study. JAMA Dermatol. 2023;159(10):1124-128. doi:10.1001/jamadermatol.2023.2787
Link BG, Phelan JC. Conceptualizing stigma. Annual Review of Sociology. 2001;27:363-385. doi:10.1146/annurev.soc.27.1.363.
Krüger C, Schallreuter KU. Stigmatisation, avoidance behaviour and difficulties in coping are common among adult patients with vitiligo. Acta Derm Venereol. 2015;95(5):553-558. doi:10.2340/00015555-1981.
Thompson AR, Clarke SA, Newell RJ, Gawkrodger DJ; Appearance Research Collaboration (ARC). Vitiligo linked to stigmatization in British South Asian women: a qualitative study of the experiences of living with vitiligo. Br J Dermatol. 2010;163(3):481-486. doi:10.1111/j.1365-2133.2010.09828.x
Thompson AR, Kent G, Smith JA. Living with vitiligo: dealing with difference. Br J Health Psychol. 2002;7(Pt 2):213-225. doi:10.1348/135910702169457.
Castellano-Lopezosa L, Ureña Paniego C, Haselgruber S, Blasco-Morente G, Arias-Santiago S. Impact of vitiligo on major life-changing decisions and perceived stigmatization: a cross-sectional study. Acta Derm Venereol. 2025;105:adv44198. Published 2025 Aug 5. doi:10.2340/actadv.v105.44198
Lai YC, Yew YW, Kennedy C, Schwartz RA. Vitiligo and depression: a systematic review and meta-analysis of observational studies. Br J Dermatol. 2017;177(3):708-718. doi:10.1111/bjd.15199.
Padmakar S, Murti K, Pandey K, Kumari S, Kumar R, Siddiqui NA, et al. Suicidal ideation associated with vitiligo — a systematic review of prevalence and assessment. Clin Epidemiol Glob Health. 2022;17:101140. doi:10.1016/j.cegh.2022.101140
Kussainova A, Kassym L, Akhmetova A, Glushkova N, Sabirov U, Adilgozhina S, et al. Vitiligo and anxiety: a systematic review and meta-analysis. PLoS One. 2020;15(11):e0241445. doi:10.1371/journal.pone.0241445.
Osinubi O, Grainge MJ, Hong L, Ahmed A, Batchelor JM, Grindlay D, et al. The prevalence of psychological comorbidity in people with vitiligo: a systematic review and meta-analysis. Br J Dermatol. 2018;178(4):863-878. doi:10.1111/bjd.16049
Yang Y, Zapata L, Rodgers C, Hernandez K, Iyer M, Jia G, et al. Quality of life in patients with vitiligo using the Short Form-36. Br J Dermatol. 2017;177(6):1764-1766. doi:10.1111/bjd.15936.
Kurosky SK, Atkinson C, Jagun O, Cooper C, Lejeune A, Castellano G, et al. Social determinants of health, quality of life, and productivity outcomes among adults with vitiligo in Brazil, China, India, and South Africa. J Dermatol Treat. 2025;36(1).2555198. doi:10.1080/09546634.2025.2555198
Silveira LP, Grijsen ML, Follador I, Dellatorre G. How persistent stigma and discrimination keep people with visible skin diseases out of jobs: vitiligo in Brazil today. Lancet Reg Health Am. 2023;23:100524. doi:10.1016/j.lana.2023.100524.
Narayan VS, Uitentuis SE, Luiten RM, Bekkenk MW, Wolkerstorfer A. Patients' perspective on current treatments and demand for novel treatments in vitiligo. J Eur Acad Dermatol Venereol. 2021;35(3):744-748. doi: 10.1111/jdv.16927.
Eleftheriadou V, Delattre C, Chetty-Mhlanga S, Lee C, Girardat-Rotar L, Khan I, et al. Burden of disease and treatment patterns in patients with vitiligo: findings from a national longitudinal retrospective study in the UK. Br J Dermatol. 2024;191(2):216-224. doi:10.1093/bjd/ljae133.
Chernyshov PV, Tomas-Aragones L, Manolache L, Pustisek N, Salavastru CM, Marron SE, et al. Quality of life measurement in vitiligo. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes with external experts. J Eur Acad Dermatol Venereol. 2023;37(1):21-31. doi:10.1111/jdv.18593.
